Efficacy and Safety of Tacrolimus in Treating Pediatric Refractory Nephrotic Syndrome: a Meta-Analysis

Dongdong Wang,Xiao Chen,Zhiping Li
2018-01-01
Abstract:To investigate the efficacy and safety of tacrolimus (TAC) in treating pediatric refractory nephrotic syndrome (PRNS). 4 self-controlled studies of tacrolimus were evaluated to verify the therapeutic effect of tacrolimus in PRNS. 3 randomized controlled trials (RCTs) and 1 comparative cohort study were assessed to demonstrate the efficacy and safety of TAC comparing with other immunosuppressive therapies in treating PRNS. The quality of included studies were moderate. The meta-evaluation of the 4 self-controlled studies of TAC stated that TAC significantly decreased urine protein to creatinine ratio (mean difference = -5.78, 95% CI = -8.00 --3.55, P < 0.00001). Further, the 3 RCTs and 1 comparative cohort study showed that compared to mycophenolate mofetil and cyclophosphamide, TAC could achieve higher rates of complete remission (risk ratio = 1.79, 95% CI = 1.11-2.90, P = 0.02, and risk ratio = 3.07, 95% CI = 1.78-5.29, P < 0.0001, respectively). Compared with ciclosporin A, no significant difference was found in complete remission rate. But, TAC significantly reduced the adverse events of nephrotoxicity and hypertrichosis (odds ratio = 0.25, 95% CI = 0.08-0.74, P = 0.01 and odds ratio = 0.00, 95% CI = 0.00-0.02, P < 0.00001, respectively). No obvious evidence of publication bias was found. Therefore, TAC is considered a promising candidate for treating PRNS.
What problem does this paper attempt to address?